A common feature of tumor cells is the aberrant expression of ion channels on their plasma membrane. The molecular mechanisms regulating ion channel expression in cancer cells are still poorly known. K ؉ channels that belong to the human ether-a-go-go-related gene 1 (herg1) family are frequently misexpressed in cancer cells compared to their healthy counterparts. We describe here a posttranslational mechanism for the regulation of hERG1 channel surface expression in cancer cells. This mechanism is based on the activity of hERG1 isoforms containing the USO exon. These isoforms (i) are frequently overexpressed in human cancers, (ii) are retained in the endoplasmic reticulum, and (iii) form heterotetramers with different proteins of the hERG family. (iv) The USO-containing heterotetramers are retained intracellularly and undergo ubiquitin-dependent degradation. This process results in decreased hERG1 current (I hERG1 ) density. We detailed such a mechanism in heterologous systems and confirmed its functioning in tumor cells that endogenously express hERG1 proteins. The silencing of USO-containing hERG1 isoforms induces a higher I hERG1 density in tumors, an effect that apparently regulates neurite outgrowth in neuroblastoma cells and apoptosis in leukemia cells.
A common feature of tumor cells is the aberrant expression of ion channels on their plasma membrane. The molecular mechanisms regulating ion channel expression in cancer cells are still poorly known. K ؉ channels that belong to the human ether-a-go-go-related gene 1 (herg1) family are frequently misexpressed in cancer cells compared to their healthy counterparts. We describe here a posttranslational mechanism for the regulation of hERG1 channel surface expression in cancer cells. This mechanism is based on the activity of hERG1 isoforms containing the USO exon. These isoforms (i) are frequently overexpressed in human cancers, (ii) are retained in the endoplasmic reticulum, and (iii) form heterotetramers with different proteins of the hERG family. (iv) The USO-containing heterotetramers are retained intracellularly and undergo ubiquitin-dependent degradation. This process results in decreased hERG1 current (I hERG1 ) density. We detailed such a mechanism in heterologous systems and confirmed its functioning in tumor cells that endogenously express hERG1 proteins. The silencing of USO-containing hERG1 isoforms induces a higher I hERG1 density in tumors, an effect that apparently regulates neurite outgrowth in neuroblastoma cells and apoptosis in leukemia cells.
Ion channels control several cellular functions from neuronal signaling and hormone secretion to the regulation of cell volume and salt and water fluxes across epithelia (19) . Recent evidence indicates that ion channels are also relevant in the regulation of tumor establishment and progression (15) . The contribution of ion channels to the neoplastic phenotype is as diverse as the ion channel families themselves: some types of K ϩ and Cl Ϫ channels are necessary for cell proliferation (6) or are involved in the control of apoptosis (10) . K ϩ and Na ϩ channels have also been found to modulate the invasive phenotype and metastatic potential of cancer cells (24) . Sometimes, these effects can be exerted through the regulation of neoangiogenesis in tumors (31, 34) . The number and biophysical features of ion channels expressed on the plasma membrane are crucial to these physiological functions (19) . Several mechanisms control the supply of ion channels to the plasma membrane, including gene transcription and RNA processing, posttranslational modifications (glycosylation and phosphorylation, etc.), and protein degradation (29) .
We studied the regulation of the surface expression of K ϩ channels encoded by human eag (ether-à-go-go)-related gene 1 (herg1) in cancer cells. hERG1 channels are often aberrantly expressed in cancer cells, and their activity is involved in different aspects of tumor establishment and progression (5) . The biophysical features of hERG1 current (I hERG1 ) can be regulated by different mechanisms. First, hERG channels are tetramers, and both homo-and heterotetramers can occur. The coassembly of different isoforms of the hERG1 protein, as well as of channel proteins encoded by different herg genes, occurs. For example, the two full-length hERG1 isoforms (hERG1A and hERG1B) coassemble in tumor cells (14) as well as in the heart (18, 22) . The heterotetrameric interaction of proteins encoded by different erg genes has also been reported (42, 43) and gives rise to functional channels. A relevant level of control of I hERG1 is represented by the amount of hERG1 protein expressed on the cell surface. This control is mainly exerted by regulation of hERG1 protein folding and subsequent regulation of forward trafficking. This mechanism also accounts for some forms of long QT syndrome (41) . Sequences relevant to hERG1 trafficking to the plasma membrane have been identified in the C terminus of the protein (1, 2, 8, 25) . In particular, the 104-amino-acid stretch located immediately downstream of the CNB domain has the function of masking an RGR sequence, which is located downstream and behaves as an endoplasmic reticulum (ER) retention signal. This RGR retention signal becomes exposed when mutations truncate the hERG1 C terminus (26) . A physiological example of this mechanism is represented by a herg1 splice variant named herg1 USO (25) . (14) . For N-glycosidase F treatment, proteins (50 g/sample) that had been resuspended in 100 l of 20 mM sodium phosphate (pH 7.5) containing 0.1% sodium dodecyl sulfate (SDS), 0.75% Nonidet P-40, 50 mM ␤-mercaptoethanol, and protease inhibitors (Complete mini; Roche) were incubated with 10 mU of N-glycosidase F (Roche) for 17 h or without N-glycosidase F. For endoglycosidase H treatment, proteins (50 g/sample) that had been resuspended in 100 l of 50 mM sodium acetate (pH 5.5), 25 mM EDTA, 1% SDS, 0.1% Nonidet P-40, and protease inhibitors were incubated with 10 mU of endoglycosidase H (Roche) for 17 h or without endoglycosidase H. Reactions were stopped by adding reducing Laemmli buffer. For immunoprecipitation (IP) experiments, cell proteins (1 mg) were first precleared with 40 l of protein A (Sigma) (33% gel slurry) and then incubated with purified anti-USO antibodies overnight at 4°C. Protein A (30 l) was added for another 2 hours of incubation. Bound proteins were washed three times in lysis buffer and three times in PBS before heating the samples in reducing Laemmli buffer. WB was performed by using anti-pan-hERG1 (Alexis) (1:1,000), antihERG1B (Alexis) (1:500), anti-USO (Alexis) (1:500), antitubulin (Sigma) (1: 500), and antiubiquitin (clone P4G7, Stressgene) (1:250), diluted in PBS with 0.1% Tween 20, supplemented with 5% bovine serum albumin (BSA). For preabsorption experiments, anti-USO antibodies (5 l) were first incubated for 2 h at room temperature with 10 g of antigenic peptide before probing the WBs.
When required, quantitative measurement of the pixel density of fully and core-glycosylated hERG1A and/or hERG1B bands, as well as ubiquitinated hERG proteins, was performed with Scion image software (Scion Corporation). Values were normalized to the corresponding tubulin band (for hERG1A and hERG1B) or to the immunoprecipitated hERG1A band (for ubiquitin experiments).
Immunofluorescence (IF) laser confocal microscopy. HEK 293 and SH-SY5Y cells were plated onto polylysine-or laminin-coated coverslips, respectively. Forty-eight hours after transfection, cells were fixed with 3.5% paraformaldehyde in PBS for 15 min at room temperature and processed as reported in reference 12. The following primary antibodies were used: polyclonal antibodies anti-pan-hERG1 (Alexis) (1:100), anti-hERG1B (Alexis) (1:400), and anti-USO (1:400) and monoclonal antibodies anti-KDEL (Stressgene) (1:400) and anti-␤1 integrin (clone TS2/16, American Type Culture Collection) (1:50). All the primary antibodies were diluted in PBS containing 10% BSA and incubated overnight at 4°C. The following secondary antibodies were used: tetramethyl rhodamine isothiocyanate-conjugated goat anti-rabbit immunoglobulin G (Southern Biotechnology Associates) and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin G (ICN Biomedical), goat anti-mouse antibody-Alexa Fluor 488 (Invitrogen), and goat anti-rabbit antibody-Alexa Fluor 635 (Invitrogen). The former was used for HEK 293 cells, while the latter was used for SH-SY5Y cells. All the antibodies were diluted 1:500 in PBS containing 10% BSA and incubated for 1 h at room temperature. In experiments where two rabbit polyclonal antibodies were used (see Fig. 4C , panels d and e), pilot experiments were performed in order to assess that complete saturation was achieved after incubation with the first antibody, before adding the other primary antibody. Coverslips were mounted in ProLong antifade reagent (Invitrogen) and imaged with a Leica SP2-AOBS confocal microscope. Images were acquired using either a 63ϫ HCX PL APO 1.4-numerical-aperture oil immersion objective or a 40ϫ HCX PL APO 1.25 oil immersion, using a 1,024-by 1,024-pixel image format and adjusting the zoom level to match the voxel size to the Nyquist criterion. The pinhole size was always set at 1 airy unit (airy disk), and each plane Anti-pan-hERG1
The ability (ϩ) or inability (Ϫ) of the three antibodies to recognize hERG1 isoforms is shown.
b Residues 1106 to 1158 of the sequence deposited in GenBank under accession number NP_000229.
c Residues 16 to 28 of the sequence deposited in GenBank under accession number CAD54447.
d Residues 36 to 548 of of the sequence deposited in GenBank under accession number CAE82156.
was Kalman averaged three times to reduce noise. In each experiment, the same instrumental settings were used for all image acquisitions. All images were Gaussian filtered to eliminate single-pixel noise before analysis.
Quantitative colocalization analysis of antigens shown below (see Fig. 4B ) was performed on acquired images analyzed as individual channels. The Manders' overlap coefficients (M1 and M2) (30) were calculated using the intensity correlation analysis plugin of the open-source software WCIF-ImageJ (28). Manders' overlap coefficients indicate an overlap of the signals and thus represent the degree of colocalization between the red and green pixels: their values range from 0 (no overlap) to 1 (complete overlap). Briefly, the background signal on each image was initially corrected using the ImageJ background subtraction function, and whenever possible, single cells on the images were selected using the lasso tool (which defines a so-called region of interest). Colocalization was then calculated, after choosing the threshold values for the green and red channels, with the above cited plugin on the regions of interest previously defined. Zero/zero pixel was excluded. We reported only the Manders' coefficient relative to the hERG1A/KDEL overlap.
In order to quantify the plasma membrane expression of the hERG1A protein, we followed the procedure described in reference 13 with minor modifications. Briefly, the quantization of hERG1 fluorescence was conducted on z stacks of 15 sections corresponding to a thickness of approximately 2.5 m passing through the middle of the cells. Regions of interest were manually drawn around each cell, and the integrated intensity after background correction was measured in hERG1 and USO channels (Alexa Fluor 635 and Alexa Fluor 488, respectively). To account for differences in cell size, the integrated intensity in each region of interest was divided by its measured perimeter. The median value of USO intensity was calculated and used to divide the population of measured cells into two groups: low-USO-expressing cells (all cells below the median value) and high-USO-expressing cells (all cells above the median value). The distribution of the normalized integrated intensity of hERG1 in the two groups of cells was then compared and statistically tested for significance with the nonparametric twotailed Mann-Whitney test. ImageJ software was used for fluorescence quantization, and GraphPad Prism 4.0 was used for statistical analysis. Quantitative colocalization analysis of antigens was performed on acquired images analyzed as individual channels.
Electrophysiology. HEK 293 cells were cultured as described above. Approximately 2 ϫ 10 4 cells were transfected (see above) with 1 to 5 g of the appropriate plasmid, along with 0.2 g of a plasmid containing the gene for enhanced green fluorescent protein (pEGFP-C1; Clontech). Currents were recorded 24 to 72 h after transfection.
(i) Solutions and drugs. During the patch clamp experiments, cells were maintained in standard extracellular solution (130 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES-NaOH, and 5 mM D-glucose) (pH 7.4). During the specific biophysical tests, cells were perfused with a high K ϩ external solution (the concentration of K ϩ outside the cell was 20 mM), where NaCl was replaced by an equimolar amount of KCl. The pipette solution contained 130 mM K ϩ -aspartate, 10 mM NaCl, 2 mM MgCl 2 , 10 mM EGTA-KOH, 10 mM HEPES-KOH, had a pH of 7.30, and a nominal intracellular [Ca 2ϩ ] of ϳ50 nM. When needed, the specific ERG blocker WAY-123,398 (way, 40) was used at 2 M, and the resulting traces were subtracted from control traces to obtain the way-sensitive currents. The extracellular solutions were delivered through a 9-hole (0.6-mm) remote-controlled linear positioner with an average response time of 1 or 2 seconds that was placed near the cell under study. Experiments aimed at determining whether the specific ERG blocker E4031 could rescue USO isoforms that encoded ERG1 currents were performed according to reference 45, except for the incubation time extended to 48 h.
(ii) Patch clamp recordings and data analysis. ERG currents were always elicited under conditions of relatively high extracellular K ϩ concentrations (20 mM) in order to measure currents under optimal signal-to-noise conditions. The currents were recorded at room temperature by using the MultiClamp 700A (Axon Instruments) as previously described (35) . Pipette resistances were about 1.5 to 2.2 M⍀. Cell capacitance and series resistance errors were compensated (85 to 90%) before each voltage clamp protocol was run, in order to reduce the voltage errors to less than 5% of the protocol pulse. pClamp 8.2 (Axon Instruments) and Origin 7 (Microcal Inc.) software were routinely used during data acquisition and analysis. The steady-state activation curves were obtained by plotting the normalized peak tail currents at Ϫ120 mV versus the preconditioning potential (Ϫ80 to ϩ20 mV for 15 seconds), as reported previously (37) . RNA interference. The small interfering RNA (siRNA) specific for the USO exon of the herg1 USO gene (sense, 5Ј-ACA GAC ACU UUU UGC UUC CTT-3Ј) was custom synthesized by Ambion. The siRNA negative control 1 (Ambion) was used as a negative control. siRNAs were transfected using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. siRNA specific for USO-containing transcripts was used at a final concentration of 100 nM, while siRNA negative control 1 was used at a final concentration of 50 nM as recommended. In some cases, siRNA were Cy3 labeled using the Cy3 labeling kit (Ambion) following the manufacturer's instructions. Sequential excitation with a 514-nm laser line was used when imaging cells transfected with Cy3-labeled siRNA. The same approach was used to determine the percentage of siRNA-transfected cells to evaluate the effect of USO silencing.
Flow cytometry. (i) hERG1 labeling. To quantify hERG1 expression on the plasma membranes of SH-SY5Y cells transfected with siRNA USO or siRNA negative control, cells were labeled with an Alexa Fluor 488-conjugated antihuman hERG1 monoclonal antibody (1:50) produced in our laboratory and available commercially (Alexis). This antibody is specific for a 14-amino-acid peptide located in the extracellular S5-P loop of hERG1 protein, and it is able to recognize its epitope in flow cytometry in living cells (for details, see reference 33). Cells that had been previously washed with PBS were stained for 15 min at room temperature in the dark. After a careful wash to remove any aspecific background, samples were analyzed by flow cytometry on a BD FACSCalibur flow cytometer using the Diva software (BD Pharmingen).
(ii) Annexin V and PI labeling. Double staining of leukemia cells with annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) (annexin V-FLUOS staining kit; Roche) was used to analyze the apoptotic rate. Cells were resuspended in 100 l buffer (provided by the kit) and incubated with FITCconjugated annexin V and PI for 15 min at room temperature in the dark. Cells were washed once and then used for analysis by flow cytometry on a BDLSRII cytofluorimeter using the Diva software (BD Biosciences). We defined three main different cell populations, viable (annexin V negative and PI negative), Nucleotide sequence accession number. The sequence of herg1b uso has been submitted to GenBank under accession no. AJ 609614.
RESULTS
Cloning of an alternative transcript of the herg1 gene, herg1b USO . Three variants of the herg1 gene (KCNH2) have been cloned so far (Fig. 1) . We cloned a fourth variant by 3Ј rapid amplification of cDNA ends and PCR, starting from RNA extracted from neuroblastoma and leukemia cells. This variant bears the 1b exon at the 5Ј end and the USO exon at the 3Ј end. Therefore, we named this new clone herg1b USO . The structures of the four herg1 cDNAs and a list of the antibodies we developed and used to discriminate the four encoded proteins are shown in Fig. 1 and Table 1 , respectively. When the herg1 USO and herg1b USO genes and the corresponding proteins exhibit common features, they will be collectively called "USO-containing transcripts" and "USO-containing isoforms," respectively.
The hERG1B USO protein does not give rise to detectable I hERG1 in transfected cells: evidence for intracellular retention. It has been reported that hERG1 USO is unable to produce macroscopic I hERG1 when expressed in mammalian cells (25) . We verified whether this lack of current also occurred for hERG1B USO . No currents were detected even after long-term incubation with the hERG1 blocker E4031, a pharmacological tool commonly used to rescue misfolded LQT2-hERG1 mutants (45) (Fig. 2 , panels A 4 and B 4 , and the legend to Fig. 2 ). The proper expression of the transfected herg1 USO and herg1b USO constructs in the cells used for patch clamping was checked by RNase protection assay (Fig. 2C) .
The lack of expression of detectable I hERG1 in cells expressing the USO-containing isoforms could be traced back to a shortcoming of plasma membrane localization of the two isoforms, due to missing C-terminal sequences. This possibility was tested by performing WB and immunolocalization experiments ( Fig. 2D to F) . For these studies, we raised a new rabbit polyclonal antibody against a peptide located in the USO region (anti-USO antibody). The immunoreactivity and specificity of this novel antibody were first tested by WB performed on total lysates from HEK 293 cells stably transfected with herg1 USO (HEK-hERG1 USO ) and herg1b USO (HEK-hERG1B USO ) (Fig. 2D , anti-USO antibody). The antibody recognized doublets of 97 and 99 kDa in HEK-hERG1 USO cell extracts and 60 and 62 kDa in HEKhERG1B USO extracts. These results are in agreement with the predicted molecular mass (M r ) of the two USO-containing proteins ( Table 2) . The WB signals were absent when the antibody was preadsorbed with an excess of antigenic peptide (Fig. 2D , preadsorbed anti-USO antibody).
Specific enzymatic treatments of total intact cells and protein extracts were performed to better define hERG1B USO membrane localization and glycosylation state. An example is shown in Fig. 2E . The doublet representing hERG1B USO in HEK-hERG1B USO cells ( USO , and HEKhERG1B USO cells were separated by 7.5% SDS-polyacrylamide gel electrophoresis (PAGE) and blotted, and the following WB was revealed with a purified anti-USO antibody. In the right panel, the same blot was revealed with the anti-USO antibody preadsorbed with an excess antigenic peptide (Anti-USO pre-adsorbed). (E) WBs of proteins extracted from hERG1B and hERG1B USO cells after enzymatic treatments. Total lysates from HEK-hERG1B USO (left panel) and HEK-hERG1B (right panel) cells were subjected to SDS-PAGE as described above for panel D, and the following WBs were revealed with anti-USO antibodies and anti-hERG1B (anti-1B). Lanes: PK, proteinase K (cleavage of proteins expressed on the plasma membranes of intact cells); NF, N-glycosidase F (removal of all glycans from glycosylated proteins); EH, endoglycosidase H (removal of high-mannose oligosaccharides added during core glycosylation of newly synthesized proteins in the ER, before being sorted to the Golgi apparatus). Note that the band of higher M r (ϳ100 kDa) disappeared in HEK-hERG1B cells treated with PK, while the 85-kDa band was unaffected by PK treatment as expected. Moreover, when hERG1B protein was treated with NF, a shift of the 100-kDa band toward the 85-kDa band was observed. Furthermore, EH digestion shifted the 85-kDa band to lower M r , while leaving the 100-kDa band unaltered. The same experiments performed on HEK-hERG1A gave the expected protein band pattern (46; also data not shown). The positions of molecular mass markers (in kilodaltons) are indicated to the left of the gels in panels D and E. (F) Cellular localization of hERG1 isoforms. HEK 293 cells, transiently transfected with herg1a (panels a to c and a' to c'), herg1b (d to f and d' to f'), herg1 USO (g to i and g' to i') and herg1b USO (j to l and j' to l'), were double labeled with the polyclonal anti-hERG(s) antibodies indicated to the left of panels a, d, g, j and a', d', g', and j' and with monoclonal antibodies anti-KDEL (panels b, e, h, and k) or anti-␤1 integrin (panels b', e', h', and k') antibodies. Merged images are in panels c, f, i, and l (for KDEL) and c', f', i', and l' (for ␤1-integrin). Bar, 10 m (applies to all panels). We also performed IF experiments to confirm these results (Fig. 2F) . HEK 293 cells were transiently transfected with the four herg1 isoforms, and after the cells were permeabilized, they were probed with the corresponding antibodies (Table 1) , along with either an anti-KDEL antibody (that recognizes a motif shared by a subset of ER-resident chaperones) (Fig. 2F , panels a to l), or an anti-␤ 1 integrin antibody (that mainly stains cell surface integrins) (Fig. 2F , panels a' to l'). In herg1a-and herg1b-transfected cells, the encoded proteins showed both intracellular and plasma membrane distribution (Fig. 2F , panels a to f and a' to f'). On the other hand, the hERG1 USO and hERG1B USO proteins showed only intracellular staining that mostly merged with the anti-KDEL staining (Fig. 2F , panels g to l) and did not colocalize with the ␤ 1 integrin (panels g' to l').
hERG1B USO decreases I hERG1 density when coexpressed with current-encoding hERG1 isoforms. It has been previously reported that expression of hERG1 USO in hERG1A-transfected cells induced a decrease in I hERG1 density (25) . We tested whether the same occurred for hERG1B USO and whether there was a selectivity of the USO-containing isoforms for the corresponding current-encoding counterparts. Hence, we measured the average current density of HEK 293 cells cotransfected with herg1a or herg1b as a control, plus either herg1 USO or herg1b USO . The results of these experiments are collectively shown in Fig. 3A . Cotransfection with the USOcontaining cDNAs produced a significant inhibition of the currents compared to controls. No selectivity of the two USO-containing isoforms (hERG1 USO and hERG1B USO ) for the corresponding current-encoding proteins (hERG1A and hERG1B, respectively) was observed.
The USO-induced inhibition of the average current density could also in turn alter the biophysical characteristics of the functional channels, hERG1A and hERG1B. To test this possibility, we analyzed one of the most sensitive biophysical parameters, namely, the deactivation time constants of the current elicited at Ϫ120 mV. Various mixtures of the cDNAs used for transfections were tested. All data are reported in Fig. 3B to D. We combined either herg1 USO or herg1b USO cDNAs with herg1a or herg1b. Data obtained from cells cotransfected with herg1a and herg1b are also reported and represent the controls relative to the effects of coassembly of two different hERG1 isoforms (23) . In Fig. 3B , C, and D are reported the values of the fast and slow time constants and the ratio of the fast time constant to the total amplitude, respectively. As expected, the fast time constants of I hERG1 in cells cotransfected with herg1a and herg1b [ Fig. 3B , hERG(1Aϩ1B)] are quite different from those registered in cells transfected with the single cDNAs. This result indicates that different hERG1 monomers can coassemble to form functional heterotetramers with biophysical properties which are intermediate between those of the corresponding homotetramers (23) . No difference was found between controls and HEK 293 cells cotransfected with the USOcontaining cDNAs. The same analysis performed on the slow component (Fig. 3C ) of the deactivation current gave identical results. Also, the amplitude ratio, shown in Fig. 3D , did not result in significant differences.
Finally, we tested whether USO-containing isoforms exerted the same effects on channels other than the hERG1A and hERG1B channels. We chose one channel, hERG3, that belongs to the same family and another channel, Kv 1.1, that belongs to an unrelated family of voltage-dependent K ϩ channels. It emerged that cotransfection of herg1b USO along with herg3 strongly (Ͼ90%) reduced the hERG3 current compared to herg3-transfected cells (Fig. 3A, hERG3 and ϩBUSO 2 bars). On the other hand, cotransfection of herg1b USO along with Kv 1.1 did not significantly alter the amount of Kv current (Fig. 3A , hKv 1.1 1 and ϩBUSO 2 bars). These results indicate that the regulatory role of USO-containing isoforms on the amount of the detectable I hERG is family specific, with no effect on K ϩ channels belonging to unrelated families. The USO-containing isoforms coassemble with and regulate the trafficking of full-length hERG1 isoforms to the plasma membrane in transfected cells. The results reported above were interpreted on the assumption that both hERG1 USO and hERG1B USO proteins coassembled and hence formed heterotetramers with hERG1A and/or hERG1B. We then experimentally verified this hypothesis. For this purpose, protein extracts from HEK-hERG1 USO or HEK-hERG1B USO cells and cotransfected with either herg1a or herg1b were immunoprecipitated with anti-USO antibody, and the following WB was revealed with the anti-pan-hERG1 antibody (Fig. 4A) . As evident in the left gel of Fig. 4A , the anti-USO antibody was able to immunoprecipitate only one protein band from HEK 293 cells coexpressing herg1a and herg1 USO (lane HEKhERG1USOϩherg1a). The M r of this band corresponds to the M r of the core-glycosylated, ER-resident, form of the hERG1A protein (135 kDa). Similarly, also in HEK 293 cells coexpressing herg1b and herg1 USO (lane HEK-hERG1USOϩherg1b) and in HEK 293 cells coexpressing either herg1b or herg1a and herg1b USO (Fig. 4A , right gel, lanes HEK-hERG1USOϩherg1b and HEK-hERG1USOϩherg1a), the anti-USO antibody immunoprecipitated only the core-glycosylated forms of hERG1B and hERG1A, respectively. To better localize the full-length hERG1 proteins in cells expressing the USO isoforms, we performed double IF experiments on HEK-hERG1 USO and HEK-hERG1B USO cells cotransfected with either herg1a or herg1b. Hence, all the cells expressed the stably transfected cDNA, although at different intensities, while only some of them expressed the cotransfected isoform. The latter could be visualized by using the antibody specific for the full-length hERG1 proteins (anti-panhERG1). In any case, the latter antibodies were used in conjunction with either anti-KDEL or anti-␤ 1 integrin antibodies. Representative images relative to HEK-hERG1 USO cells cotransfected with herg1a are shown in Fig. 4B and C. The hERG1A protein colocalized with KDEL and hence was present in the ER, when coexpressed with an USO transcript (Fig. 4B, panel c) . The localization of hERG1A in the ER also occurs in cells transfected with only herg1a (Fig. 2F, panel a) . We quantified the colocalization of hERG1A with KDEL in cells expressing only hERG1A and in cells coexpressing hERG1 USO and hERG1A through the calculation of the Manders' coefficient (see Materials and Methods and the legend to Fig. 4) . It emerged that hERG1A is more localized in the ER when expressed with hERG1 USO (Fig. 4B, panel d) . These results suggest that hERG1 heterotetramers are retained in the ER, if a USO-containing subunit is present in the tetramer.
We also evaluated whether hERG1A colocalized with a plasma membrane protein, when coexpressed with hERG1 USO . To do this, HEK-hERG1 USO cells cotransfected with herg1a were labeled with both anti-pan-hERG1 and anti-␤ 1 integrin antibodies. Only a partial merge of the two signals was observed (Fig. 4C, panel c) . Finally, we quantified the plasma membrane expression of hERG1A when coexpressed with an USO isoform through the following approach: HEKhERG1 USO cells cotransfected with herg1a were labeled with anti-USO (Fig. 4C, panel d) and anti pan-hERG1 (Fig. 4C , panel e) antibodies. As expected, all the cells expressed the hERG1 USO protein, although at different intensities. Two groups of cells were identified, those expressing low levels (see the white arrow in Fig. 4C , panel d) and those expressing high levels of the USO protein (see the white asterisks in Fig. 4D,  panel d) . In the two groups of cells, the plasma membrane expression of the hERG1A protein was quantified as described previously (13) . It emerged that cells displaying a low expression of hERG1 USO had the highest level of hERG1A expressed on the plasma membrane (see the white arrow in Fig.  4C , panel c), and vice versa (see the white asterisks in Fig. 4C , panel e). The different plasma membrane expression of the hERG1A protein in the two USO-expressing cell populations was statistically significant (P Ͻ 0.0001) (Fig. 4C, panel f) .
To better define this point, we performed cotransfection experiments in which the amount of herg1a or herg1b was kept constant, while the amount of cotransfected herg1 USO or herg1b USO was progressively increased from an equimolar concentration to a 20-fold excess. Cellular proteins were then extracted, and the following blot was revealed with anti-panhERG1 antibody. Results are reported in Fig. 5A to C. When herg1 USO (Fig. 5A ) or herg1b USO (Fig. 5B) was coexpressed with herg1a, a significant decrease of mature (155-kDa) hERG1 proteins was observed. Similar results were obtained for the hERG1B protein (Fig. 5C ). When amounts of USOcontaining cDNAs above fourfold excess were used, a significant decrease in the core-glycosylated forms of both hERG1A and hERG1B proteins was also observed. Quantitative data are reported in the bar graphs in Fig. 5A , B, and C. These results suggest that the USO-containing subunits cause strong retention of heterotetramers in the ER, thus inducing an overall decrease in channel protein expression, with a subsequent impairment of their insertion into the plasma membrane. This effect could rely on increased channel degradation, possibly through ubiquitination and subsequent clearing through the proteasomal pathway. We tested this latter possibility by cotransfecting different amounts of herg1 USO along with a constant amount of herg1a, both in the absence and presence of the proteasome inhibitor MG-132. Proteins were immunoprecipitated with the anti-USO antibody, and the following WB was revealed with antiubiquitin antibody which recognizes both mono-and polyubiquitinated proteins. Results are reported in Fig. 5D . It is evident that the level of ubiquitination increases when higher amounts of herg1 USO (4 and 10 times) are cotransfected with herg1a (Fig. 5D, top gel, lanes 3 and 5) . In addition, the block of the proteasome through the specific inhibitor MG-132 significantly increased the level of ubiquitination (Fig.  5D, top gel, lanes 4 and 6) . Reprobing the blot with anti-panhERG1 antibodies (Fig. 5D, bottom gel) shows the presence of the core-glycosylated, 135-kDa hERG1A protein in the immunoprecipitate. Hence, comparing the bottom and top gels in Fig. 5D , we can argue that the hERG1A protein undergoes ubiquitination when it coassembles with hERG1 USO . Reprobing the blot also shows that the immunoprecipitated hERG1A protein increases in MG-132-treated cells, as expected. The graph at the bottom of Fig. 5D shows the results of densitometric analysis of the level of ubiquitinated hERG1A protein.
The data clearly show that hERG1A undergoes a significant ubiquitination when expressed with hERG1 USO and that hERG1A channels are likely to be cleared by the proteasome.
Expression of herg1b USO in healthy and neoplastic human tissues. The expression of herg1b USO transcript in selected human tissues and cell lines was analyzed by Northern blotting using an USO-specific probe. The probe also recognized herg1 USO in tissues where it was expressed. The two transcripts can be discriminated on the basis of their length. Figure 6A shows a Northern blot of total RNA extracted from HEKhERG1B USO , human heart, FLG 29.1 leukemia, and SH-SY5Y neuroblastoma cells. A larger band (3.8 kb) can be tissues (Fig. 6B) . Apart from the high-level expression of herg1 USO in the heart, both herg1 USO and herg1b USO were expressed at very low levels in the tissues examined. We detected faint bands relative to both herg1 USO and herg1b USO in brain, spleen, and colon, while herg1b USO could be barely detected in placenta, pancreas, and kidney. The expression of USO-containing transcripts was also quantified by Sybr green RQ-PCR in human tissues. Some of the transcripts were the same as those present in the blot, while others were chosen on the basis of their level of expression of the current-encoding herg1 transcripts (herg1a and herg1b) in humans or rats (38, 44) . Results are reported in Fig. 6C (USO  transcripts) . The quantitative expression of herg1a and herg1b in the same tissues are also reported (herg1a and herg1b graphs). Note that RQ-PCR data do not allow discriminating whether the USO signal can be attributed to herg1 USO or herg1b USO , except in those cases where only herg1a or herg1b transcripts are present. A high level of USO-containing mRNA was confirmed in human heart where the signal is attributable to herg1 USO , as indicated by Northern blot data. Moderate levels of USO-containing transcripts were also found in brain and thymocytes. No expression of any of the herg1 transcripts could be detected in peripheral blood mononuclear cells and adherent cell-depleted peripheral blood lymphocytes. The USO-containing transcripts were also detected at very low levels in testis and pancreatic ␤-cells. Figure 6D shows the quantitative expression of USO-containing transcripts in tumor cell lines and primary tumors, in which the current-encoding transcripts (herg1a and herg1b) were previously shown to be expressed (14, 27, 34) . The USOcontaining transcripts are always expressed at high levels in tumor cell lines and primary tumors.
Finally, we tested whether the USO-containing transcripts were properly translated into USO-containing proteins in tumor cells. WB experiments exploiting the anti-USO antibody were therefore performed on several tumor cell lines, including those used for RQ-PCR analysis. Figure 6E shows that, in tumor cell protein extracts, the anti-USO antibody revealed two groups of bands; bands around 97 kDa correspond to hERG1 USO , while those around 60 kDa correspond to hERG1B USO . All tumor cell lines examined expressed both hERG1 USO and hERG1B USO , although at different intensities. FLG 29.1 cells expressed exclusively bands corresponding to hERG1B USO , while colon carcinoma cell lines expressed bands of slightly different molecular weights (see Discussion). On the whole, USO-containing proteins are expressed in tumor cells, in accordance with Northern blot and RQ-PCR data.
hERG1 USO and hERG1B USO are retained intracellularly and coassemble with current-encoding hERG1 isoforms in tumor cells. We then examined whether the USO-containing isoforms were retained intracellularly also in cells where they are physiologically expressed. We tested this possibility by evaluating whether the USO-containing isoforms coimmunoprecipitated with the current-encoding hERG1 proteins in tumors, as occurs in transfected cells. SH-SY5Y neuroblastoma cells and FLG 29.1 leukemia cells were used as a model. Total lysates were immunoprecipitated with the anti-USO antibody, and the following WB was revealed with anti-pan-hERG1. In SH-SY5Y cells (Fig. 7A) , the anti-USO antibody was able to immunoprecipitate only the immature, ER-resident, hERG1A and hERG1B (compare Fig. 7A with Fig. 4A , HEKhERG1USOϩherg1a and HEK-hERG1USOϩherg1b lanes). Correspondingly, in FLG 29.1 cells (Fig. 7B) , which express only hERG1B and hERG1B USO , the anti-USO antibody only immunoprecipitated the immature, ER-resident, hERG1B protein. Total lysates of both SH-SY5Y and FLG 29.1 cells, probed with the anti-USO antibody are shown in the rightmost gels in Fig. 7A and B, respectively.
Collectively, these data suggest that the functional role of USO-containing isoforms that was demonstrated in transfected cells likely occurs in physiological systems.
Physiological roles of hERG1 USO and hERG1B USO in tumor cells: regulation of hERG1 trafficking and I hERG1 density. We further confirmed this conclusion by knocking down hERG1 USO and hERG1B USO in tumor cells through RNA interference (Fig. 8 ). An siRNA against the USO sequence (siRNA USO) was designed and synthesized. The efficiency of this siRNA in silencing hERG1 USO and hERG1B USO was first tested on HEK-hERG1 USO and HEK-hERG1B USO cells. Figure 8A shows that the siRNA USO efficiently impairs the translation of hERG1 USO in transfected cells (a similar effect was exerted on hERG1B USO [not shown]). To simulate the physiological situation, HEK 293 cells were then cotransfected with herg1 and herg1 USO ; a significant downregulation of the hERG1A protein was observed (Fig. 8B , lane HEK-hERG1A/ 1USOϩsiRNA negative control), as already reported (Fig. 5A) . The siRNA-mediated hERG1 USO silencing restored hERG1A expression (Fig. 8B , lane HEK-hERG1A/1USOϩsiRNAUSO) to levels comparable to those detected in HEK 293 cells transfected with only herg1a (lane HEK-hERG1A). The same effects were obtained in HEK 293 cells cotransfected with herg1b and herg1b USO (not shown).
Finally, we tested the effect of the siRNA USO on tumor cells. In this case, transfected cells turned out to be about 40% of the cells (see Materials and Methods and the legend to Fig.  8 ). Figure 8C shows that the siRNA USO was efficient in decreasing the expression of both hERG1 USO and hERG1B USO in SH-SY5Y cells (panel c); this effect was accompanied by a significant increase in both hERG1A (panel c') and hERG1B (panel c' and c") proteins. The results are more evident in the densitometric analysis in the graph at the bottom of Fig. 8C . To analyze whether the siRNA USO produced an increase of hERG1A expression on the cell surface, we performed IF experiments (Fig. 8D) . SH-SY5Y cells were transfected with the siRNA USO and labeled with anti-pan-hERG1 antibodies. Images were taken from the same culture dish. It is evident that cells properly transfected with the siRNA USO (Fig. 8D,  panel d') show numerous discrete spots on the plasma membrane neurites, an aspect not detectable in neighboring, nontransfected cells (panel d) (see also the insets in panels d' and d at higher magnifications) or in cells transfected with the siRNA negative control (not shown). This feature is suggestive of an increased expression of the hERG1 proteins on the plasma membrane, a hypothesis confirmed by flow cytometry (Fig. 8E) . To examine this hypothesis, SH-SY5Y cells were labeled with a monoclonal antibody raised in our laboratory that recognizes the S5-S6 extracellular loop of the hERG1 protein. Hence, when used without cell permeabilization, this antibody marks only the hERG1 proteins expressed on the plasma membrane. Figure 8E shows that a greater percentage Strikingly, a significant increase in I hERG1 density recorded from SH-SY5Y cells transfected with the siRNA USO compared to either siRNA-transfected cells (negative control) or nontransfected cells accompanied these findings (Fig. 8F) .
Finally, we asked whether the USO-mediated control of hERG1 channel expression could have relevance in any biological aspect of tumor cells. On the basis of previous observations for neuroblastoma cells (3, 4) , we tested whether the USO isoforms could play a role in modulating neurite outgrowth in these cells. In Fig. 9A , it is evident that the number of neurites per cell significantly increases in SH-SY5Y cells transfected with the siRNA USO compared to cells transfected with the siRNA negative control (P ϭ 0.02).
Another relevant function of hERG1 channels is their regulatory role in the growth of leukemia cells (32, 39) . Hence, we tested the effects of siRNA USO on both cell cycle progression and induction of apoptosis on leukemia cell lines. While cell cycle progression was not affected by siRNA USO treatment (not shown), such treatment induced a significant increase in the percentage of apoptotic cells in all the leukemia cell lines analyzed (Fig. 9B) . Two representative examples of the flow cytometry data relative to the annexin V test in the RS cell line are shown (Fig. 9B , graphs to the right) (see the legend to Fig.  9B for details) .
DISCUSSION
In this study we provide evidence of a novel mechanism that regulates the surface expression of K ϩ channels of the hERG1 family in tumor cells. This mechanism is based on the expression of isoforms that are retained in the ER and form heterotetramers with isoforms that are properly targeted to the cell surface and thus modulate their expression level on the plasma membrane. Specifically, two hERG1 proteins that contain the USO sequence at the C terminus (hERG1 USO and hERG1B USO ) modulate forward trafficking of the two fulllength hERG1 isoforms (hERG1A and hERG1B). This mod- (25) and a novel transcript we cloned from tumor cells. The novel transcript presents the USO exon at the C terminus and the 1b exon at the N terminus and was hence named herg1b USO . From various healthy human tissues, we detected a high expression of herg1 USO only in the heart. Both herg1 USO and herg1b USO transcripts were expressed at high levels in human tumors. Interestingly, a significant correlation was found between the levels of expression of USO-containing transcripts and those of current-encoding isoforms in leukemias, where the latter data are published (see Table 3 in reference 34). Moreover, USO-containing transcripts were properly translated in tumor cells. A leukemia cell line, FLG 29.1, expressed only hERG1B USO , while colon carcinoma cells expressed USO proteins of lower molecular weight. This result is suggestive of the presence of specific USO variants at least in some tumor cells.
The functioning and physiological role of USO-containing isoforms in both heterologous systems and tumor cells was defined. First, we showed that the two USO-containing isoforms do not give rise to functional channels when heterologously expressed in mammalian cells, because they are retained intracellularly at the ER level ( Fig. 2 and 3) . The ER retention of the two USO-containing isoforms also occurs in tumor cells (Fig. 7) . The ER entrapment of USO-containing isoforms could be predicted by the absence in these proteins of the part of the hERG1 C terminus implicated in channel maturation (8, 21, 26) , in particular the RGR sequence (26) . We obtained experimental demonstration of these predictions through the development and use of a novel anti-USO antibody. In addition, we showed that the ER retention of the USO-containing isoforms is not due to protein misfolding, as occurs for some long QT syndrome mutants (36) . In fact, neither the addition of the hERG1 blocker E4031 nor lowering the temperature (not shown), two different procedures commonly used to rescue the proper plasma membrane expression of various long LQT syndrome 2 mutants (45), ensues in significant I hERG (Fig. 2, panels A 4 and B 4 ) .
A novel finding emerging from our data is the demonstration that the USO-containing isoforms can form heterotetramers with the full-length hERG1 proteins. In particular, the USO-containing isoforms coassembled with the core-glycosylated, ERresident hERG1 full-length proteins. This finding was supported by biochemical and IF data gathered on transfected cells (Fig. 4) and in tumor cells (Fig. 7) . This implies that heterotetramers comprising USO-containing isoforms are entrapped in the ER. We also showed that this entrapment produces a decrease in the expression of mature hERG1A and hERG1B proteins and hence in the number of channels that reach the plasma membrane. This occurred in both heterologous systems (Fig. 5 ) and tumor cells. We indirectly showed this latter point using RNA interference (Fig. 8) . In heterologous systems, when the USO-containing isoforms were expressed at higher levels than the full-length hERG1 proteins were, an overall decrease in channel protein was also observed (Fig. 6) . Hence, USO-containing isoforms could both entrap current-encoding hERG1 proteins in the ER and also interfere with the trafficking of the proteins toward the plasma membrane, when the levels of expression of the USO isoforms strongly exceed those of the full-length hERG1 proteins. The USO-dependent decrease in full-length hERG1 protein expression is apparently due to an increase of protein ubiquitination and hence to the induction of protein degradation in the proteasome. In other words, hERG1 USO or hERG1B USO might exert a "chaperone-like" function, similar to, although with slight differences with, that reported for Hsp90 (16) , arsenic trioxide (17), or ceramide (11) .
Finally, we demonstrated that the USO-containing hERG1 isoforms are physiologically relevant in regulating the amount of functional I hERG1 expressed on the plasma membrane. In fact, cotransfection of herg1 USO and herg1b USO with full-length, current-encoding isoforms lead to a significant decrease in I hERG1 density (Fig. 3) . This decrease occurred without any (HEK-hERG1A) , herg1a/herg1 USO at a 1:10 ratio plus siRNA negative control (HEK-hERG1A/1 USO ϩsiRNA negative control), and herg1a/herg1 USO at a 1:10 ratio plus siRNA USO (HEK-hERG1A/1 USO ϩsiRNA USO ). Total lysates (5 g) were run through a 7.5% SDS-polyacrylamide gel, and the following WB was revealed with anti-pan-hERG1, anti-USO, and antitubulin antibodies. Mock-transfected HEK 293 cells (HEK-MOCK) are shown in the leftmost lanes of panels A and B. (C) Effects of siRNA USO on hERG1A and hERG1B expression in SH-SY5Y cells. SH-SY5Y cells were treated with siRNA USO and siRNA negative control. Total lysates (40 g) were run through a 7.5% SDS-polyacrylamide gel, and the following WB was revealed with anti-USO, anti-pan-hERG1, anti-hERG1B, and antitubulin antibodies. Densitometric analysis was performed on hERG1A and hERG1B bands modification of I hERG1 biophysical properties. This fact confirms that USO-containing isoforms simply decrease the fraction of hERG1 channels reaching the plasma membrane. The I hERG1 -decreasing effect was exerted by hERG1 USO or hERG1B USO on hERG channels encoded by different genes of this family (such as herg3). On the other hand, this mechanism is completely absent for K ϩ channels belonging to different families, such as the Kv 1.1 channels presented in this paper.
The relevant aspect of our data is the demonstration that in addition to heterologous systems, the USO-dependent modulation of hERG1 proteins and of I hERG1 also occurs in tumor cells. We used RNA interference to demonstrate this point, mainly using neuroblastoma and leukemia cells as a model. siRNA USO was able to increase the expression of currentencoding hERG1 isoforms and their localization onto the plasma membranes of tumor cells (Fig. 8C to E) . This effect results in a doubling of I hERG1 in tumor cells (Fig. 8F) . In addition, siRNA USO treatment induces an increase of neurite outgrowth in neuroblastoma cells and of cellular apoptosis in leukemia cells.
We can speculate that the significance of the USO-mediated regulation of hERG1 channel surface expression in the heart could be that of regulating I Kr in pathological conditions. For example, during heart failure, a decrease in K ϩ currents, including I Kr , has been reported. This decrease is not accompanied by a concomitant decrease in RNA transcription of K ϩ current-encoding genes. This apparent paradox could be interpreted with an upregulation of hERG1 USO in these conditions. However, the main question we have tentatively addressed in the present paper is the significance of the USO-mediated mechanism in tumor cells. On the basis of data presented herein and according to reference 5, we hypothesize that oncogenic transformation is accompanied by a herg1 gene(s) switching on. Both full-length and USO-containing isoforms are expressed and assemble in the ER. Only tetramers composed by full-length, current-encoding hERG1 isoforms can reach the plasma membrane. A definite number of functional hERG1 channels on the plasma membrane can in turn control various behavioral features of tumor cells, such as cell proliferation and invasion (6) . This can occur either through the clamping of the voltage resting membrane potential to values compatible with cell proliferation or through the well-established modulatory role of hERG1 channels in cell signaling (7, 34) . When I hERG1 activity is blocked through specific hERG1 inhibitors, cell proliferation and invasion are concurrently impaired (34) , leading to the restoration of a healthy, hERG1-devoid, biophysical profile. When a hERG1 channel density on the cell surfaces of tumor cells that is too high is produced (by either silencing USO-containing isoforms or increasing hERG1 expression through retinoic acid treatment [4] ), impairment of cell proliferation through the induction of either cell differentiation or apoptosis ensues. On the whole, proper control of hERG1 protein surface expression is necessary in tumor cells, and the USO-containing isoforms could help in providing the proper number of functional hERG1 channels on the plasma membranes of tumor cells. This hypothesis is outlined in Fig. 10 . In this light, the block of the USO-based mechanism of hERG1 channel trapping, through RNA interference, could have therapeutic significance in cancer cells. 
